Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2019-01-31 Audit Report / Informat…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변경
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from a Korean company (Samil Pharmaceutical) announcing a significant change in financial structure (revenue or profit/loss change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for preliminary financial results before the final audit report is filed. Since it provides key financial highlights and performance metrics rather than a full annual report or a simple announcement of a report's availability, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial performance. FY 2018
2019-01-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large-Scale Shareholding' (주식등의 대량보유상황보고서) filed under the Capital Markets Act in South Korea. It details changes in share ownership by major shareholders (insiders) and their special related parties, including specific transaction dates, methods (e.g., open market purchases), and the source of funds. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership changes that cross reporting thresholds.
2019-01-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. It details share transactions (장내매수 - on-market purchase) by an executive/major shareholder (Heo Seung-beom) of Samil Pharmaceutical. This type of filing is classified as a Director's Dealing (DIRS) report, as it documents insider share transactions.
2019-01-02 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Samil Pharmaceutical. It details specific transactions (purchases) made by major shareholders and directors, including the name of the individual (Heo Seung-beom), the date of change, the number of shares, and the resulting ownership percentage. This falls under the category of Director's Dealing (DIRS) as it reports personal share transactions by company directors and major shareholders.
2018-12-28 Korean
분기보고서 (2018.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Samil Pharmaceutical Co., Ltd. for the period ending September 30, 2018. It contains detailed financial statements, business operations, management analysis, and governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2018
2018-11-13 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Samil Pharmaceutical. It details specific changes in share ownership by individuals classified as major shareholders or their relatives (e.g., Seo Hyun-jung). This type of filing is a standard regulatory requirement in South Korea for reporting insider or major shareholder transactions, which falls under the category of 'Major Shareholding Notification' (MRQ).
2018-10-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.